Sotorasib improves PFS versus docetaxel in patients with pre-treated KRAS G12C-mutated NSCLC
Results from the CodeBreaK 200 trial represent an improvement for a difficult-to-treat patient population
Could anti-PD-L1 be the best choice as front-line therapy in platinum-ineligible patients with NSCLC?
Findings show overall survival benefits with front-line atezolizumab versus single-agent chemotherapy, but questions remain regarding who might benefit
Lack of clinical benefit with adjuvant canakinumab in completely resected NSCLC
Negative results from the CANOPY-A trial do not support use in the adjuvant setting
A pathway from air pollution to lung cancer in non-smokers has been identified
In a study presented at ESMO Congress 2022, air pollution is shown to drive interleukin-1β release in cells with EGFR mutations to promote lung cancer development
Perioperative survival after bilobectomy is worse than lobectomy
Although bilobectomy remains a valid procedure, comparatively high mortality rates indicate that cautious use and appropriate patient counselling is required
Encouraging safety data for the use of durvalumab after sequential chemotherapy in stage III unresectable NSCLC
Findings from the PACIFIC-6 trial echo the benefits seen with durvalumab after concomitant chemoradiotherapy, representing a potential alternative for vulnerable and older patients
Results for two new third-generation EGFR tyrosine kinase inhibitors do not suggest advantages over osimertinib
Alternatives to osimertinib for first-line treatment of EGFR-mutated NSCLC are explored among Asian populations
Atezolizumab shows little heterogeneity in efficacy in high PD-L1 expressers with stage II–IIIA NSCLC
Results from the subgroup analysis of the IMpower010 study also report some patterns of relapse that are in contrast with previously presented findings
Assessing pathological response after neoadjuvant treatment for NSCLC
Much progress has been made in the standardisation of pathological response but optimising viable tumour cutoffs for predicting long-term outcome after different treatment modalities and by histological type remain key areas for investigation
Encouraging results with savolitinib in NSCLC with MET exon14 skipping mutations
Overall survival data are in line with those from other MET tyrosine kinase inhibitors and show promise in a tumour subtype with poor prognosis